ECMO: A Bridge to Healing, or a Bridge to Nowhere?

ECMO is supportive care, not definitive therapy: the right question is whether the patient has a realistic bridge to recovery, transplant, durable support, or at least a decision point. In cardiogenic shock and severe respiratory failure, candidate selection matters as much as cannulation speed.

When ECMO Is The Wrong Answer

• Bridge concept first: ECMO buys time but does not fix the underlying disease, so every consult starts with a destination: recovery, transplant, durable support, or a short bridge to decision.
• Bridge to nowhere risk: The major pitfall is cannulating a patient with no meaningful exit strategy, especially when recovery is unlikely and transplant or LVAD candidacy is off the table.
• Maximal therapy requirement: ECMO should follow disease-specific maximal medical therapy, whether that means cath lab for STEMI, OR for valvular catastrophe, or fully exhausted asthma management.
• Recovery and comorbidity screen: Meaningful candidacy hinges on the underlying pathology, baseline function, and organ-level comorbidities such as ESRD, cirrhosis, or advanced malignancy. We get into the practical screening mindset in the episode.
• Center-specific contraindications: Many exclusions are local and expert-opinion based, but severe neurologic injury, poor life expectancy, and end-stage peripheral organ disease are consistent red flags.

VV Versus VA ECMO Decisions

• Respiratory versus hemodynamic support: VV ECMO is generally for isolated respiratory failure, while VA ECMO supports both oxygenation and circulation when shock and hypoxemia collide.
• Emergency department use pattern: VA ECMO shows up more often in the ED because crashing patients frequently have combined cardiac and respiratory collapse rather than a pure oxygenation problem.
• Cannulation consequence awareness: VA ECMO returns blood retrograde into the arterial system, a detail that explains why severe aortic regurgitation can become catastrophic with LV dilation and clot burden.
• Vascular access limitations: Extensive peripheral vascular disease can make large-bore cannulation unsafe or impossible, with acute limb ischemia as one of the headline complications.
• Dissection as a danger zone: Acute aortic dissection with major branch involvement is a high-risk scenario because wires or cannulas may enter the false lumen. That procedural concern is worth hearing in the chapter.

Cardiogenic Shock And ECMO Selection

• Shock phenotype matters: ELSO frames ECMO-suitable cardiogenic shock around persistent hypoperfusion despite optimal treatment, with markers like hypotension, oliguria, elevated lactate, and low SVO2.
• SCAI staging anchor: For STEMI-related shock, SCAI staging helps separate who may warrant escalation, and the practical ECMO conversation usually starts in the refractory D to E range.
• Stage C caution: Recent data do not support routine upfront ECMO for SCAI stage C cardiogenic shock, reinforcing that earlier cannulation is not automatically better.
• Disease-specific bridge planning: A STEMI patient needs revascularization, not just pump support; ECMO makes sense when it is clearly buying time to a fix rather than replacing one.
• ECPR as bridge to decision: Extracorporeal CPR is the classic bridge-to-decision scenario, where ECMO creates a window to clarify neurologic prognosis and downstream candidacy.

References:

1. Gajkowski EF et al. ELSO Guidelines for Adult and Pediatric Extracorporeal Membrane Oxygenation Circuits. ASAIO J. 2022 Feb 1;68(2):133-152. Erratum in: ASAIO J. 2022 Jul 1;68(7):e131. PMID: 35089258.
2. Ostadal et al. ; ECMO-CS Investigators. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. Circulation. 2023 Feb 7;147(6):454-464. Epub 2022 Nov 6. PMID: 36335478.